AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Novonesis AS

Transaction in Own Shares Aug 3, 2015

3377_dirs_2015-08-03_b76aa753-faeb-47b3-8a79-dd1634f66c66.pdf

Transaction in Own Shares

Open in Viewer

Opens in native device viewer

August 3, 2015

As of July 31, Novozymes has purchased an accumulated 3,711,047 shares with a transaction value of DKK 1,200.2 million under the stock buyback program Novozymes announced in Company announcement No. 6, 2015 and initiated February 2, 2015. Under the program, Novozymes will buy back B shares worth up to DKK 2 billion in total during 2015.

The following transactions have been made under the program in accordance with the provisions of European Commission Regulation (EC) No. 2273/2003 of 22 December 2003, also referred to as the Safe Harbour Regulation:

Number of shares Average purchase price Transaction value, DKK
Accumulated, last announcement 3,553,881 1,145,225,787
27 July 2015 31,500 347.35 10,941,425
28 July 2015 29,500 347.74 10,258,239
29 July 2015 34,000 349.22 11,873,388
30 July 2015 30,700 350.04 10,746,151
31 July 2015 31,466 354.24 11,146,470
Accumulated under the program 3,711,047 1,200,191,460

In addition, transactions necessitated by Novozymes' previously established incentive programs have resulted in a net sale by Novozymes of 2.570 B shares in the period from July 27 to July 31, 2015. The share transactions related to the incentive programs were not part of the Safe Harbour stock buyback program.

Following the transactions stated above, Novozymes owns a total of 7,545,364 treasury shares, corresponding to 2.4% of the stock capital. The total number of shares in the company is 313,000,000 including treasury shares.

Contact information

Investor Relations:
Thomas Bomhoff (DK) +45 3077 1226 [email protected]
Klaus Sindahl (DK) +45 5363 0134 [email protected]
Martin Riise (USA) +1 919 649 2565 [email protected]

About Novozymes

Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com

NASDAQ OMX: NZYM-B ● 6,500 employees ● 12B DKK turnover ● 30+ industries ● 700+ products

Talk to a Data Expert

Have a question? We'll get back to you promptly.